Search results
Adding Isatuximab to Standard Backbone Improves Outcomes in Multiple Myeloma
MedPage Today· 3 days agoTwo trials show positive outcomes
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of...
Morningstar· 5 days agoGilead and Arcus Announce EtrumadenantPlus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer – In Cohort B of the ARC-9 mCRC Study, Etrumadenant ...
EMA CHMP recommends AstraZeneca’s Tagrisso for lung cancer
Pharmaceutical Technology via Yahoo Finance· 3 days agoIn May 2024, AstraZeneca signed a global licence and option agreement with Nona Biosciences for a...
Celularity reports advances in cancer T-cell therapy By Investing.com
Investing.com· 4 days agoCelularity Inc. (NASDAQ: CELU), a biotechnology firm specializing in regenerative medicine,...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
The Woonsocket Call· 3 days agoSyndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on June 1, 2024 the Company granted ...
OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating...
Benzinga· 2 days agoOSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant At the American Transplant Congress 2024 (June 1-5 Philadelphia) Nantes,
S2 Episode 3: How Do You Treat Refractory Colorectal Cancer?
Medscape· 2 days agoFor more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify,...
Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of...
KOIN News 6 Portland· 4 days agoInnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that...
Humans May Be Able to Grow New Teeth Within Just 6 Years
Popular Mechanics· 4 days agoNow, Japanese researchers are moving a promising, tooth-regrowing medicine into human trials—the...
Pierre Fabre Laboratories Announce IND Filing for PFL-002/VERT-002, a Potential Treatment for...
KETK· 2 days agoPierre Fabre Laboratories today announced the filing of an investigational new drug ("IND") application to the U.S. Food and Drug Administration ("FDA") to initiate a first-in-human (FIH) Phase ...